Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Share-based Compensation (2022 - 2025)

Oramed Pharmaceuticals' Share-based Compensation history spans 4 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation changed N/A year-over-year to $2.3 million; the TTM value through Dec 2025 reached $6.0 million, changed N/A, while the annual FY2025 figure was $5.2 million, 27.12% up from the prior year.
  • Share-based Compensation reached $2.3 million in Q4 2025 per ORMP's latest filing, up from $2.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q1 2022 to a low of -$8.9 million in Q4 2022.
  • Average Share-based Compensation over 4 years is $614333.3, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: crashed 165.05% in 2023, then soared 647.98% in 2024.
  • A 4-year view of Share-based Compensation shows it stood at -$8.9 million in 2022, then soared by 77.81% to -$2.0 million in 2023, then surged by 115.17% to $301000.0 in 2024, then soared by 673.42% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Share-based Compensation are $2.3 million (Q4 2025), $2.2 million (Q1 2025), and $301000.0 (Q3 2024).